<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841421</url>
  </required_header>
  <id_info>
    <org_study_id>STB017</org_study_id>
    <nct_id>NCT04841421</nct_id>
  </id_info>
  <brief_title>Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors</brief_title>
  <official_title>Clinical Study on Positron Emission Tomography (PET) Imaging, Distribution and Pharmacokinetics of 89 Zirconium (Zr)-CD147 in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinotau Pharmaceutical Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinotau Pharmaceutical Group</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to observe the distribution of 89Zr-CD147 and&#xD;
      radiation dosimetry characteristics in patients with solid tumors. The secondary objective is&#xD;
      to observe the pharmacokinetic characteristics of 89Zr-CD147 in patients with solid tumors.&#xD;
      This study is a single-center, open-lable study, including 89Zr-CD147 1mCi±10%，89Zr-CD147&#xD;
      3mCi±10% and 89Zr-CD147 5mCi±10% dose group. The trial is expected to last for 2 years from&#xD;
      the first patient signing the consent form to the end of the trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance&#xD;
      to visualize and characterize tumor lesions. Additionally, it can be used to identify&#xD;
      patients who may benefit from a particular therapy and monitor the therapy outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value (SUV)</measure>
    <time_frame>Day 0-7</time_frame>
    <description>Standardized uptake value of tumor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>standardized uptake value ratio (SUVR)</measure>
    <time_frame>Day 0-7</time_frame>
    <description>The ratio of the standardized uptake value of the tumor or suspected tumor lesion to the standardized uptake value of normal tissue</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiation dose</measure>
    <time_frame>Day 0-7</time_frame>
    <description>Radiation dose of whole body and major tissues / organs of subjects after administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Time (T1/2)</measure>
    <time_frame>Day 0-7</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Day 0-7</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 0-7</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 0-7</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution (dL)</measure>
    <time_frame>Day 0-7</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>89Zr-CD147 1mCi±10% 10mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The activity administered was 1mCi±10% and the mass of radiolabeled CD147 was 10 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>89Zr-CD147 3mCi±10% 10mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The activity administered was 3mCi±10% and the mass of radiolabeled CD147 was 10 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>89Zr-CD147 5mCi±10% 10mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The activity administered was 5mCi±10% and the mass of radiolabeled CD147 was 10 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>89Zr-CD147</intervention_name>
    <description>The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.</description>
    <arm_group_label>89Zr-CD147 1mCi±10% 10mg dose group</arm_group_label>
    <arm_group_label>89Zr-CD147 3mCi±10% 10mg dose group</arm_group_label>
    <arm_group_label>89Zr-CD147 5mCi±10% 10mg dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be between 18 and 70 years old (including 18 and 70 years old), male or&#xD;
             female;&#xD;
&#xD;
          2. Patients with advanced solid tumors (stage IV): non-small cell lung cancer (NSCLC);&#xD;
             Gastric adenocarcinoma; Colorectal adenocarcinoma, etc ;&#xD;
&#xD;
          3. Patients must have an ECOG performance status of 0-1;&#xD;
&#xD;
          4. Patients must have a life expectancy ≥ 12 weeks;&#xD;
&#xD;
          5. Patients must have adequate organ function:&#xD;
&#xD;
             White blood cell (WBC) count≥4.0x10^9/L or absolute neutrophil count (ANC) ≥1.5 x&#xD;
             10^9/L, Platelets ≥100 x 10^9/L, Hemoglobin≥ 90g/L ; thrombin time or Activated&#xD;
             partial thromboplastin time≤1.5ULN; liver and renal function: Total bilirubin≤1.5ULN&#xD;
             (upper limit of normal), Alanine aminotransferase (ALT) or aspartate aminotransferase&#xD;
             (AST)≤2.5ULN or ≤5ULN (subjects with liver metastasis), alkaline phosphatase (ALP)≤&#xD;
             2.5ULN (if there is bone metastasis or liver metastasis ALP≤4.5ULN). Urea&#xD;
             (BUN)≤1.5ULN, creatinine≤1.5ULN;&#xD;
&#xD;
          6. Patients must have ≥1 measurable lesion according to RECIST1.1 criteria;&#xD;
&#xD;
          7. For patients who have partners of childbearing potential: Partner and/or patient must&#xD;
             use a method of birth control with adequate barrier protection, deemed acceptable by&#xD;
             the principle investigator during the study and for 6 months after last study drug&#xD;
             administration.;&#xD;
&#xD;
          8. Patients must have the ability to understand and sign an approved ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There are any of the following conditions, such as brain metastasis (except for&#xD;
             asymptomatic primary or metastatic brain tumors that do not need treatment),&#xD;
             carcinomatous meningitis, myocardial infarction (within 6 months before enrollment),&#xD;
             unstable angina pectoris, or high risk of uncontrollable arrhythmia, coronary artery&#xD;
             bypass grafting, cerebrovascular accident (within 6 months before enrollment),&#xD;
             congestive heart failure (cardiac function grade III-IV), pulmonary embolism, deep&#xD;
             venous thrombosis, Infections that need to be treated with intravenous antibiotics&#xD;
             within 2 weeks, and immunosuppressant therapy after organ transplantation;&#xD;
&#xD;
          2. Primary central nervous system tumor;&#xD;
&#xD;
          3. HBV DNA≥1000 copies/ml;&#xD;
&#xD;
          4. HCV-RNA≥1000 copies/ml;&#xD;
&#xD;
          5. People with positive antibodies to HIV or syphilis;&#xD;
&#xD;
          6. Patients with acute or subacute intestinal obstruction, or a history of inflammatory&#xD;
             bowel disease;&#xD;
&#xD;
          7. Women who are pregnant, breastfeeding or planning pregnancy;&#xD;
&#xD;
          8. People who are known to be allergic to the study preparation or its auxiliary&#xD;
             materials;&#xD;
&#xD;
          9. People with a history of psychotropic substance abuse and inability to get rid of it&#xD;
             or mental disorders;&#xD;
&#xD;
         10. Patients who cannot lie for half an hour;&#xD;
&#xD;
         11. Patients who are allergic to any component of the imaging agent or antibody;&#xD;
&#xD;
         12. Patients who cannot accept PET/CT imaging;&#xD;
&#xD;
         13. Situations that other researchers consider unsuitable to participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yue Chen, PHD</last_name>
    <phone>13700989831</phone>
    <email>chenyue5523@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Qiu, PHD</last_name>
    <phone>15984011133</phone>
    <email>qiulin17111210041@163.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Hospital Of Southwest Medical University</investigator_affiliation>
    <investigator_full_name>Yue Chen</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

